91�㽶��Ƶ

SOMERSET, N.J. – January 29, 2020 – 91�㽶��Ƶ, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced the appointment of Ricci Whitlow as President, Clinical Supply Services. Ms. Whitlow succeeds Paul Hegwood, who, following a period of transition, plans to retire in March 2020 after a career of nearly 45 years in operations, business development, and engineering roles.

Ms. Whitlow’s position will continue to report to Alessandro Maselli, the company’s President and Chief Operating Officer. As President of the business unit, she will have global responsibility for all aspects of 91�㽶��Ƶ’s clinical supply business, which, in fiscal 2019, generated $321.4 million in revenue and $84.4 million in Segment EBITDA. 91�㽶��Ƶ’s clinical supply network includes nine cGMP-certified clinical packaging, storage, and distribution facilities across North America, Europe and Asia, and more than 50 strategically located depots around the world, providing local and regional options for clinical storage, distribution, expiry update and relabeling services, and clinical returns management.

Ms. Whitlow has over 25 years’ experience in commercial, operations, and general management roles within the pharmaceutical biologics and medical device industry, and she rejoins 91�㽶��Ƶ after two-and-a-half years, having previously held the position of VP Operations, overseeing nine manufacturing facilities across North and South America. Her most recent position was with OptiNose, where she served as Senior Vice President of Technical and Corporate Operations, and she has also worked for LifeCell and Johnson & Johnson during her career. Ms. Whitlow holds a master’s degree in business administration from the TRIUM program of NYU Stern School of Business, London School of Economics and HEC Paris; as well as a Bachelor of Science in Industrial Engineering from Texas A&M University. She is also a certified Six Sigma green belt.

“The clinical supply business is a key component of 91�㽶��Ƶ’s business strategy, and Ricci rejoins the company following the launch of new initiatives that are helping to guide sponsors in optimizing their clinical trial supply planning and will provide them with new direct-to-patient supply options,” commented Mr. Maselli.“ Ricci’s expertise in operations and manufacturing, as well as her previous experience at 91�㽶��Ƶ, make her the ideal person to strengthen and grow this business as the needs of global trials evolve.” He added, “We would like to thank Paul for his service to 91�㽶��Ƶ, and particularly for his tireless work as a strong advocate for the company’s ‘Patient First’ philosophy. We wish him all the best in his retirement.”

To find out more about 91�㽶��Ƶ’s clinical supply services, visit .

ABOUT CATALENT

91�㽶��Ƶ is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. With over 85 years serving the industry, 91�㽶��Ƶ has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. 91�㽶��Ƶ employs over 13,000 people, including over 2,400 scientists and technicians, at more than 35 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. 91�㽶��Ƶ is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com

 

More products. Better treatments. Reliably supplied.™